ADC raises $86.6 million in PIPE financing and amends royalty, loan deals to extend cash runway into 2029

 

• Amended royalty and loan agreements expected to reduce debt and remove a change‑of‑control payment requirement.
• ADC reports preliminary Q3 ZYNLONTA net sales of $21 million.
• ADC Therapeutics reports a total cash balance of $189.2 million.

https://finviz.com/stock?t=ADCT&p=d